000821111 001__ 821111
000821111 005__ 20210129224759.0
000821111 0247_ $$2doi$$a10.1093/neuonc/now154
000821111 0247_ $$2ISSN$$a1522-8517
000821111 0247_ $$2ISSN$$a1523-5866
000821111 0247_ $$2WOS$$aWOS:000386162800016
000821111 0247_ $$2altmetric$$aaltmetric:11629427
000821111 0247_ $$2pmid$$apmid:27591333
000821111 037__ $$aFZJ-2016-06354
000821111 082__ $$a610
000821111 1001_ $$0P:(DE-HGF)0$$aKebir, Sied$$b0
000821111 245__ $$aDynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases
000821111 260__ $$aOxford$$bOxford Univ. Press$$c2016
000821111 3367_ $$2DRIVER$$aarticle
000821111 3367_ $$2DataCite$$aOutput Types/Journal article
000821111 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1479386048_19624
000821111 3367_ $$2BibTeX$$aARTICLE
000821111 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000821111 3367_ $$00$$2EndNote$$aJournal Article
000821111 520__ $$aIdentifying patients with pseudoprogression, which is characterized by an initial increase of contrast-enhancing lesions that resolve or at least stabilize spontaneously on follow-up imaging without any treatment change, is critical for avoiding premature termination of potentially effective treatment. With the advent and success of checkpoint inhibitors such as ipilimumab, nivolumab, or pembrolizumab in particular, detecting pseudoprogression in patients with malignant melanoma has become a major challenge in clinical practice given a frequency as high as 7%–10% of cases.1,2 Diagnosing progressive disease and excluding pseudoprogression in melanoma metastases using the immune-related Response Criteria (irRC)2 require the initial increase of at least 25% in lesions load to be confirmed by follow-up imaging at least 4 weeks later.2 However, particularly for brain metastases from malignant melanoma, follow-up imaging might not be feasible for patients with clinical deterioration at the time of initial increase of lesions load. These patients might not be able to wait 4 weeks for a follow-up investigation to decide on 
000821111 536__ $$0G:(DE-HGF)POF3-573$$a573 - Neuroimaging (POF3-573)$$cPOF3-573$$fPOF III$$x0
000821111 588__ $$aDataset connected to CrossRef
000821111 7001_ $$0P:(DE-HGF)0$$aRauschenbach, Laurèl$$b1
000821111 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b2
000821111 7001_ $$0P:(DE-HGF)0$$aSchlaak, Max$$b3
000821111 7001_ $$0P:(DE-HGF)0$$aHattingen, Elke$$b4
000821111 7001_ $$0P:(DE-HGF)0$$aLandsberg, Jennifer$$b5
000821111 7001_ $$0P:(DE-HGF)0$$aBundschuh, Ralph A.$$b6
000821111 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b7
000821111 7001_ $$0P:(DE-HGF)0$$aScheffler, Björn$$b8
000821111 7001_ $$0P:(DE-HGF)0$$aHerrlinger, Ulrich$$b9
000821111 7001_ $$0P:(DE-HGF)0$$aGlas, Martin$$b10$$eCorresponding author
000821111 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/now154$$gVol. 18, no. 10, p. 1462 - 1464$$n10$$p1462 - 1464$$tNeuro-Oncology$$v18$$x1523-5866$$y2016
000821111 8564_ $$uhttps://juser.fz-juelich.de/record/821111/files/Neuro%20Oncol-2016-Kebir-1462-4.pdf$$yRestricted
000821111 8564_ $$uhttps://juser.fz-juelich.de/record/821111/files/Neuro%20Oncol-2016-Kebir-1462-4.gif?subformat=icon$$xicon$$yRestricted
000821111 8564_ $$uhttps://juser.fz-juelich.de/record/821111/files/Neuro%20Oncol-2016-Kebir-1462-4.jpg?subformat=icon-1440$$xicon-1440$$yRestricted
000821111 8564_ $$uhttps://juser.fz-juelich.de/record/821111/files/Neuro%20Oncol-2016-Kebir-1462-4.jpg?subformat=icon-180$$xicon-180$$yRestricted
000821111 8564_ $$uhttps://juser.fz-juelich.de/record/821111/files/Neuro%20Oncol-2016-Kebir-1462-4.jpg?subformat=icon-640$$xicon-640$$yRestricted
000821111 8564_ $$uhttps://juser.fz-juelich.de/record/821111/files/Neuro%20Oncol-2016-Kebir-1462-4.pdf?subformat=pdfa$$xpdfa$$yRestricted
000821111 909CO $$ooai:juser.fz-juelich.de:821111$$pVDB
000821111 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b2$$kFZJ
000821111 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b7$$kFZJ
000821111 9131_ $$0G:(DE-HGF)POF3-573$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vNeuroimaging$$x0
000821111 9141_ $$y2016
000821111 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000821111 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2015
000821111 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000821111 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000821111 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000821111 915__ $$0StatID:(DE-HGF)0550$$2StatID$$aNo Authors Fulltext
000821111 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEURO-ONCOLOGY : 2015
000821111 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000821111 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000821111 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000821111 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000821111 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000821111 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000821111 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000821111 9201_ $$0I:(DE-82)080010_20140620$$kJARA-BRAIN$$lJARA-BRAIN$$x2
000821111 980__ $$ajournal
000821111 980__ $$aVDB
000821111 980__ $$aUNRESTRICTED
000821111 980__ $$aI:(DE-Juel1)INM-3-20090406
000821111 980__ $$aI:(DE-Juel1)INM-4-20090406
000821111 980__ $$aI:(DE-82)080010_20140620
000821111 981__ $$aI:(DE-Juel1)INM-4-20090406